You are here: Home: HOU 2 | 2008 Audio: HOU 2 | 2008
 
 
  Go to interview with Steven D Gore, MD
Go to interview with Michael J Keating, MB, BS
Go to interview with William I Bensinger, MD
Go to interview with Fredrick B Hagemeister, MD
 


To listen to individual tracks, click on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
     
Gore, MD Steven D Gore, MD
Professor of Oncology
Johns Hopkins University
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland
  
  Click here to download the entire interview  
Track 1 Phase III randomized trial comparing azacitidine to conventional care regimens in high-risk myelodysplastic syndrome (MDS)
Track 2 Use of azacitidine versus decitabine in clinical practice
Track 3 Allogeneic stem cell transplantation in patients previously treated with azacitidine
Track 4 Epigenetic deregulation of MDS and acute myelogenous leukemia (AML)
Track 5 Entinostat: A histone deacetylase (HDAC) inhibitor
Track 6 HDAC inhibitors: Mechanisms of action

Track 7 Side effects and toxicities of HDAC inhibitors
Track 8 Investigation of HDAC inhibitors in other tumor types
Track 9 Discussing the diagnosis of MDS with patients
Track 10 Epidemiology of MDS
Track 11 Case discussion: A 39-year-old man who enrolled in a Phase I trial of azacitidine with entinostat
Track 12 Referral of patients to MDS Centers of Excellence
     
Keating, MD Michael J Keating, MB, BS
Professor of Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas
  
  Click here to download the entire interview  
Track 1 Role of watchful waiting in chronic lymphocytic leukemia (CLL)
Track 2 Prognostic factors in CLL
Track 3 Clinical presentations of CLL
Track 4 Treatment selection in CLL
Track 5 Therapeutic strategies under investigation in CLL
Track 6 Incorporation of alemtuzumab and bendamustine in the treatment of CLL
Track 7 Side effects associated with alemtuzumab and bendamustine

Track 8 Alemtuzumab in combination with rituximab for CLL
Track 9 Future therapeutic approaches for CLL
Track 10 Clinical use of imatinib in chronic myelogenous leukemia (CML)
Track 11 Assessment of response to therapy in CML
Track 12 Treatment for patients who are intolerant or resistant to imatinib
Track 13 Future research strategies in CML
Track 14 CLL: Autoimmune complications and diagnosing transformation
     
Besinger, MD William I Bensinger, MD
Professor of Medicine, University of Washington
Member, Hutchinson Cancer Research Center
Seattle, Washington		  
  Click here to download the entire interview  
Track 1 Treatment of multiple myeloma (MM) in community practice
Track 2 Incorporation of novel therapeutic agents and strategies by community oncologists in the treatment of MM
Track 3 Role of stem cell transplantation for MM in an era of rapidly developing novel therapeutics
Track 4 Impact of lenalidomide and bortezomib on stem cell collection
Track 5 Novel combinations with thalidomide, bortezomib or lenalidomide versus VAD-based therapies prior to transplant
Track 6 FHCRC-2123.00: A Phase II clinical trial of cyclophosphamide, bortezomib, dexamethasone and thalidomide (VEL-CTD) in newly diagnosed MM

Track 7 Use of doublet versus triplet combination therapies in the up-front treatment of MM
Track 8 Side effects and tolerability of VEL-CTD in newly diagnosed MM
Track 9 Prevention of thrombosis associated with IMiD®-based therapy
Track 10 ECOG-E4A03: Lenalidomide with high-dose or low-dose dexamethasone in newly diagnosed MM
Track 11 Maintenance therapy with IMiDs (thalidomide or lenalidomide) after transplant
Track 12 Incorporation of liposomal doxorubicin in the management of MM

Track 13 Randomized study of “cryotherapy” during administration of high-dose melphalan to decrease oral mucositis
Track 14 Melphalan/prednisone (MP) versus MP/thalidomide or MP/bortezomib for patients with newly diagnosed MM who are ineligible for transplant
Track 15 Treatment algorithm for patients with newly diagnosed MM
Track 16 Bisphosphonates in the management of MM

Track 17 Bisphosphonate-associated osteonecrosis of the jaw

     
Hagemeister, MD Fredrick B Hagemeister, MD
Professor of Medicine
The University of Texas MD Anderson Cancer Center
Department of Lymphoma/Myeloma
Houston, Texas		  
  Click here to download the entire interview  
Track 1 New agents being evaluated in the treatment of lymphomas
Track 2 DENSE-R-CHOP-14 trial: Dose-dense rituximab in elderly patients with diffuse large B-cell lymphoma
Track 3 Clinical use of R-CHOP-14
Track 4 Tolerability of R-CHOP-14 in older patients
Track 5 DENSE-R-CHOP-14 trial: Study design and results
Track 6 Impact of rituximab serum levels on disease progression

Track 7 Bendamustine versus chlorambucil for treatment-naïve patients with B-cell CLL: Pivotal trial results
Track 8 Bendamustine-R versus CHOP-R in the first-line treatment of indolent and mantlecell lymphomas
Track 9 Integration of bortezomib into treatment regimens for lymphomas